| 1 |
Kapur P, Rajaram S, Brugarolas J. The expanding role of BAP1 in clear cell renal cell carcinoma. Hum Pathol 2023;133:22-31. [PMID: 35932824 DOI: 10.1016/j.humpath.2022.07.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 2023;20:133-57. [PMID: 36414800 DOI: 10.1038/s41585-022-00676-0] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 3 |
Cheng M, Duzgol C, Kim TH, Ghafoor S, Becker AS, Causa Andrieu PI, Gangai N, Jiang H, Hakimi AA, Vargas HA, Woo S. Sarcomatoid renal cell carcinoma: MRI features and their association with survival. Cancer Imaging 2023;23:16. [PMID: 36793052 DOI: 10.1186/s40644-023-00535-0] [Reference Citation Analysis]
|
| 4 |
Climent C, Soriano S, Bonfill T, Lopez N, Rodriguez M, Sierra M, Andreu P, Fragio M, Busquets M, Carrasco A, Cano O, Seguí MA, Gallardo E. The role of immunotherapy in non-clear cell renal cell carcinoma. Front Oncol 2023;13:941835. [PMID: 36816976 DOI: 10.3389/fonc.2023.941835] [Reference Citation Analysis]
|
| 5 |
Rustum YM, Reis R, Rustum TM. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy. Int J Mol Sci 2023;24. [PMID: 36674417 DOI: 10.3390/ijms24020902] [Reference Citation Analysis]
|
| 6 |
Shan L, Shao X, Gu L, Wu M, Lin P, Yu Z, Chen Q, Zhu D. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.922150] [Reference Citation Analysis]
|
| 7 |
Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
|
| 8 |
Trassl L, Stathopoulos GT. KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player. Cancers (Basel) 2022;14:4303. [PMID: 36077838 DOI: 10.3390/cancers14174303] [Reference Citation Analysis]
|
| 9 |
Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, Su J, Yin M, Sznol M, Ariyan S, Clune J, Olino K, Parida L, Nikolaus J, Zhang M, Zhao S, Wang Y, Huang G, Wan M, Li X, Cao J, Yan Q, Chen X, Newman AM, Halaban R. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun 2022;13:898. [PMID: 35197475 DOI: 10.1038/s41467-022-28566-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Spagnoli L, Petrelli F, Fratini G, De Nisi MC, Camerini A, Giusti A, Perotti B, Cavazzana A, Arganini M, Ambrosio MR. A look towards the clonal origin of metastatic pulmonary carcinosarcoma: Report of a patient with an unexpected long-term survival. Tumori 2022;:3008916221077142. [PMID: 35168438 DOI: 10.1177/03008916221077142] [Reference Citation Analysis]
|
| 12 |
Lee E, Guan P, Lim AH, Loh JW, Tan GF, Loh T, Ng DYX, Lee JY, Goh S, Liu W, Ng CC, Teh BT, Chan JY. Multiregion sequencing of sarcomatoid renal cell carcinoma arising from autosomal dominant polycystic kidney disease. Mol Genet Genomic Med 2022;:e1853. [PMID: 35122417 DOI: 10.1002/mgg3.1853] [Reference Citation Analysis]
|
| 13 |
Marazioti A, Krontira AC, Behrend SJ, Giotopoulou GA, Ntaliarda G, Blanquart C, Bayram H, Iliopoulou M, Vreka M, Trassl L, Pepe MAA, Hackl CM, Klotz LV, Weiss SAI, Koch I, Lindner M, Hatz RA, Behr J, Wagner DE, Papadaki H, Antimisiaris SG, Jean D, Deshayes S, Grégoire M, Kayalar Ö, Mortazavi D, Dilege Ş, Tanju S, Erus S, Yavuz Ö, Bulutay P, Fırat P, Psallidas I, Spella M, Giopanou I, Lilis I, Lamort AS, Stathopoulos GT. KRAS signaling in malignant pleural mesothelioma. EMBO Mol Med 2021;:e13631. [PMID: 34898002 DOI: 10.15252/emmm.202013631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer CP, Iwata T, Parizi MK, Sauter G, Fisch M, Shariat SF, Dahlem R, Rink M. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. Front Surg 2021;8:763271. [PMID: 34869564 DOI: 10.3389/fsurg.2021.763271] [Reference Citation Analysis]
|
| 15 |
Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep 2021;37:110055. [PMID: 34818533 DOI: 10.1016/j.celrep.2021.110055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 16 |
Yoshikawa Y, Yamada Y, Emi M, Atanesyan L, Smout J, de Groot K, Savola S, Nakanishi-Shinkai Y, Kanematsu A, Nojima M, Ohmuraya M, Hashimoto-Tamaoki T, Yamamoto S. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification. Cancer Sci 2021. [PMID: 34687579 DOI: 10.1111/cas.15170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Agaimy A, Hartmann A, Trpkov K, Hes O. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol 2021;38:152-62. [PMID: 34579992 DOI: 10.1053/j.semdp.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci 2021;22:6237. [PMID: 34207825 DOI: 10.3390/ijms22126237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol 2021;17:245-61. [PMID: 33144689 DOI: 10.1038/s41581-020-00359-2] [Cited by in Crossref: 139] [Cited by in F6Publishing: 137] [Article Influence: 69.5] [Reference Citation Analysis]
|
| 20 |
Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of sarcomatoid differentiation in renal cell carcinoma by machine learning on multiparametric MRI. Sci Rep 2021;11:3785. [PMID: 33589715 DOI: 10.1038/s41598-021-83271-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 22 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 23 |
Zhu Z, Liu X, Li W, Wen Z, Ji X, Zhou R, Tuo X, Chen Y, Gong X, Liu G, Zhou Y, Chen S, Song L, Huang J. A rare multiple primary sarcomatoid carcinoma (SCA) of small intestine harboring driver gene mutations: a case report and a literature review. Transl Cancer Res 2021;10:1150-61. [PMID: 35116442 DOI: 10.21037/tcr-20-2829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Rong C, Zhou R, Wan S, Su D, Wang SL, Hess J. Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer. Front Oncol 2020;10:592501. [PMID: 33585209 DOI: 10.3389/fonc.2020.592501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Marazioti A, Blanquart C, Krontira AC, Pepe MAA, Hackl CM, Iliopoulou M, Lamort A, Koch I, Lindner M, Hatz RA, Wagner DE, Papadaki H, Antimisiaris SG, Psallidas I, Spella M, Giopanou I, Lilis I, Grégoire M, Stathopoulos GT. KRASsignalling in malignant pleural mesothelioma.. [DOI: 10.1101/2020.10.22.350850] [Reference Citation Analysis]
|
| 27 |
Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 28 |
Dudek AZ, Baxstrom K, Bharadwaj S, Blaes A, Kulkarni A, Lou E, Nehru V, Rabinovich E, Shergill A, Viner M. Genomic Strategies for Personalized Cancer Therapy. Precision Medicine in Oncology 2020. [DOI: 10.1002/9781119432487.ch1] [Reference Citation Analysis]
|
| 29 |
Testa U, Pelosi E, Castelli G. Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel) 2020;7:E44. [PMID: 32751108 DOI: 10.3390/medicines7080044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Obeng RC, Arnold RS, Ogan K, Master VA, Pattaras JG, Petros JA, Osunkoya AO. Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis. Int J Urol 2020;27:790-7. [PMID: 32638444 DOI: 10.1111/iju.14302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE 3rd, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep 2019;27:1781-1793.e4. [PMID: 31067463 DOI: 10.1016/j.celrep.2019.04.048] [Cited by in Crossref: 62] [Cited by in F6Publishing: 45] [Article Influence: 20.7] [Reference Citation Analysis]
|
| 32 |
Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 2020;16:435-51. [PMID: 32561872 DOI: 10.1038/s41581-020-0301-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 33 |
Eichenauer T, Shadanpour N, Kluth M, Göbel C, Weidemann S, Fraune C, Büscheck F, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Burandt E, Bernreuther C, Minner S, Simon R, Sauter G, Wilczak W, Clauditz T. Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World J Surg Oncol 2020;18:128. [PMID: 32534597 DOI: 10.1186/s12957-020-01902-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Alaiwi SA, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant’angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-ivins M, Hirsch L, Wind-rotolo M, Ross-macdonald P, Sun M, Lee GM, Chang SL, Wei XX, Mcgregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, Mcdermott DF, Heng DY, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors.. [DOI: 10.1101/2020.05.28.121806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 35 |
Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, Oda Y. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features. Virchows Arch 2020;477:651-60. [PMID: 32447490 DOI: 10.1007/s00428-020-02839-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 36 |
Light A, Ahmed A, Dasgupta P, Elhage O. The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. BJU Int 2020;126:26-54. [PMID: 32306543 DOI: 10.1111/bju.15084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 37 |
Soares A, Monteiro FSM, Maluf FC, Bastos DA, Jardim DL, Sasse AD, Gonçalves E Silva A, Fay AP, da Rosa DAR, Wierman E, Kater F, Schutz FA, de Oliveira FNG, Morbeck IAP, Rinck JA Jr, da Trindade KM, Maia MC, Souza VC, da Silva Neto DCV, de Almeida E Paula F, Korkes F, Carvalhal GF, Nogueira L, de Carvalho Fernandes R, Dos Reis RB, Matheus WE, Busato WFS Jr, da Costa WH, de Cássio Zequi S. Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). J Cancer Res Clin Oncol 2020;146:1829-45. [PMID: 32410064 DOI: 10.1007/s00432-020-03236-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 38 |
Ferronika P, Kats-Ugurlu G, Haryana SM, Utoro T, Rinonce HT, Danarto R, de Lange K, Terpstra MM, Sijmons RH, Westers H, Kok K. Mutational heterogeneity between different regional tumour grades of clear cell renal cell carcinoma. Exp Mol Pathol 2020;115:104431. [PMID: 32259515 DOI: 10.1016/j.yexmp.2020.104431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 39 |
Yoon JY, Gedye C, Paterson J, Ailles L. Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored. BMC Cancer 2020;20:272. [PMID: 32245446 DOI: 10.1186/s12885-020-06733-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 40 |
Ooms AHAG, Vujanić GM, D'Hooghe E, Collini P, L'Herminé-Coulomb A, Vokuhl C, Graf N, Heuvel-Eibrink MMVD, de Krijger RR. Renal Tumors of Childhood-A Histopathologic Pattern-Based Diagnostic Approach. Cancers (Basel) 2020;12:E729. [PMID: 32204536 DOI: 10.3390/cancers12030729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 41 |
Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun 2020;23:100172. [PMID: 32252014 DOI: 10.1016/j.ctarc.2020.100172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 42 |
Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM. Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma. J Korean Med Sci 2020;35:e31. [PMID: 32030920 DOI: 10.3346/jkms.2020.35.e31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 43 |
de Lima Guido LP, Hanly F, Escobedo B, Pinto A, Jorda M. Ancillary Studies Applied to Renal Masses. Renal Mass Biopsy 2020. [DOI: 10.1007/978-3-030-36036-8_12] [Reference Citation Analysis]
|
| 44 |
Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, Malouf GG. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers (Basel) 2019;12:E99. [PMID: 31906050 DOI: 10.3390/cancers12010099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 45 |
Liu J, Xiao M, Wang Y. Oral sarcomatoid squamous cell carcinoma: a retrospective study based on 14 cases. Histol Histopathol 2020;35:385-94. [PMID: 31642511 DOI: 10.14670/HH-18-176] [Reference Citation Analysis]
|
| 46 |
Park I, Lee HJ, Bae WK, Yoon S, Lee JL. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. Invest New Drugs 2019;37:1239-46. [DOI: 10.1007/s10637-019-00817-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 47 |
Suster D, Ronen S, Peterson JF, Mackinnon AC, Hes O, Suster S, Lin DI. MDM2 amplification and immunohistochemical expression in sarcomatoid renal cell carcinoma. Human Pathology 2019;87:28-36. [DOI: 10.1016/j.humpath.2019.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Hanif A, Pandey M, Khan S, Attwood K, George S. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology 2019;8:1606639. [PMID: 31413914 DOI: 10.1080/2162402X.2019.1606639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 49 |
Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 2019;11:E422. [PMID: 30934624 DOI: 10.3390/cancers11030422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 50 |
Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, Li MO, Chan TA, Motzer RJ. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discov 2019;9:510-25. [PMID: 30622105 DOI: 10.1158/2159-8290.CD-18-0957] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 51 |
Hou W, Hoefflin R, Grüllich C, Hohenfellner M, Duensing S. Molecular Heterogeneity of Renal Cell Carcinoma. Urologic Oncology 2019. [DOI: 10.1007/978-3-319-42623-5_59] [Reference Citation Analysis]
|
| 52 |
Delphine B, Damien A, Philippe B. Renal Cell Carcinoma with Sarcomatoid Features. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_9] [Reference Citation Analysis]
|
| 53 |
Sukrithan V, Sandler J, Gucalp R, Gralla R, Halmos B. Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma. Clin Lung Cancer. 2019;20:e242-e246. [PMID: 30665873 DOI: 10.1016/j.cllc.2018.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 54 |
D'Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in renal cell carcinoma. Urol Oncol 2020;38:763-73. [PMID: 30478013 DOI: 10.1016/j.urolonc.2018.10.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 55 |
Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK. Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. J Clin Oncol 2018;:JCO2018792531. [PMID: 30372389 DOI: 10.1200/JCO.2018.79.2531] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 56 |
Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Dinney C, Weinstein JN, Baggerly K, Mcconkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.. [DOI: 10.1101/388264] [Reference Citation Analysis]
|
| 57 |
Hyodo T, Kanzawa M, Hara S, Takahashi K, Ogawa S, Furukawa J, Fujisawa M, Kobayashi A, Kuroda N, Itoh T. Chromophobe renal cell carcinoma with sarcomatoid differentiation containing various heterologous components. Pathol Int 2018;68:524-9. [PMID: 30015409 DOI: 10.1111/pin.12704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 58 |
Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 59 |
Salami SS, George AK, Udager AM. The genomics of renal cell carcinoma and its role in renal mass biopsy. Curr Opin Urol 2018;28:383-91. [PMID: 29708949 DOI: 10.1097/MOU.0000000000000516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Akhtar M, Al-Bozom IA, Al Hussain T. Molecular and Metabolic Basis of Clear Cell Carcinoma of the Kidney. Adv Anat Pathol 2018;25:189-96. [PMID: 29465421 DOI: 10.1097/PAP.0000000000000185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 61 |
Liang X, Liu Y, Ran P, Tang M, Xu C, Zhu Y. Sarcomatoid renal cell carcinoma: a case report and literature review. BMC Nephrol 2018;19:84. [PMID: 29636020 DOI: 10.1186/s12882-018-0884-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 62 |
Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol 2016;26:383-7. [PMID: 27467134 DOI: 10.1097/MOU.0000000000000307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 63 |
Achkar T, Ali SM, Welsh A, Dhir R, Gollin SM, Parikh RA. A prolonged response to platinum-based therapy in a patient with metastatic urothelial carcinoma harboring a single rearranged and truncated NF2 gene. Genes Chromosomes Cancer 2018;57:430-3. [PMID: 29532557 DOI: 10.1002/gcc.22537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 64 |
Wick MR. Primary lesions that may imitate metastatic tumors histologically: A selective review. Seminars in Diagnostic Pathology 2018;35:123-42. [DOI: 10.1053/j.semdp.2017.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 65 |
Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol. 2018;244:525-537. [PMID: 29266437 DOI: 10.1002/path.5022] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 66 |
Vaishampayan U. Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. Curr Treat Options Oncol 2018;19:5. [PMID: 29368112 DOI: 10.1007/s11864-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 67 |
Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol 2018;36:265-71. [PMID: 29306556 DOI: 10.1016/j.urolonc.2017.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 68 |
Sanfrancesco JM, Cheng L. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. Critical Reviews in Oncology/Hematology 2017;119:23-8. [DOI: 10.1016/j.critrevonc.2017.09.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 69 |
Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D. Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clinical Genitourinary Cancer 2017;15:e897-901. [DOI: 10.1016/j.clgc.2017.05.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 70 |
Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 2017;123:4823-31. [PMID: 28832979 DOI: 10.1002/cncr.30937] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 71 |
Sanfrancesco JM, Eble JN, Grignon DJ, Wang M, Zhang S, Sundaram CP, Idrees MT, Pili R, Kouba E, Cheng L. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Mol Carcinog 2017;56:2527-37. [DOI: 10.1002/mc.22699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 72 |
Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res 2017;23:6686-96. [PMID: 28710314 DOI: 10.1158/1078-0432.CCR-17-1057] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 73 |
Li Y, Kang K, Krahn JM, Croutwater N, Lee K, Umbach DM, Li L. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. BMC Genomics 2017;18:508. [PMID: 28673244 DOI: 10.1186/s12864-017-3906-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 74 |
Shapiro DD, Abel EJ. Editorial Comment. J Urol 2017;198:537. [PMID: 28641080 DOI: 10.1016/j.juro.2017.04.116] [Reference Citation Analysis]
|
| 75 |
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol 2017;28:804-8. [PMID: 28049139 DOI: 10.1093/annonc/mdw676] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 76 |
Wang K, McDermott JD, Schrock AB, Elvin JA, Gay L, Karam SD, Raben D, Somerset H, Ali SM, Ross JS, Bowles DW. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol 2017;28:748-53. [PMID: 28327999 DOI: 10.1093/annonc/mdw689] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 77 |
de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer 2017;15:652-660.e1. [PMID: 28410911 DOI: 10.1016/j.clgc.2017.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 78 |
Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol. 2017;12:932-942. [PMID: 28315738 DOI: 10.1016/j.jtho.2017.03.005] [Cited by in Crossref: 84] [Cited by in F6Publishing: 100] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 79 |
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009. [PMID: 28276433 DOI: 10.1038/nrdp.2017.9] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1239] [Article Influence: 193.2] [Reference Citation Analysis]
|
| 80 |
Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, Pizzolitto S, Sioletic S, Wullich B, Hartmann A. Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency. American Journal of Surgical Pathology 2017;41:253-62. [DOI: 10.1097/pas.0000000000000787] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 81 |
Hou W, Hoefflin R, Grüllich C, Hohenfellner M, Duensing S. Molecular Heterogeneity of Renal Cell Carcinoma. Urologic Oncology 2017. [DOI: 10.1007/978-3-319-42603-7_59-1] [Reference Citation Analysis]
|
| 82 |
Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell 2016;166:950-62. [PMID: 27518565 DOI: 10.1016/j.cell.2016.07.005] [Cited by in Crossref: 150] [Cited by in F6Publishing: 160] [Article Influence: 21.4] [Reference Citation Analysis]
|
| 83 |
Gu L, Li H, Wang H, Ma X, Wang L, Chen L, Zhao W, Zhang Y, Zhang X. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2017;143:499-508. [DOI: 10.1007/s00432-016-2304-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 84 |
Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, Luchini C, Calió A, Cheng L. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Mod Pathol 2016;29:1347-57. [PMID: 27469331 DOI: 10.1038/modpathol.2016.133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 85 |
Riazalhosseini Y, Lathrop M. Precision medicine from the renal cancer genome. Nat Rev Nephrol 2016;12:655-66. [DOI: 10.1038/nrneph.2016.133] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 86 |
Ascoli V, Cozzi I, Vatrano S, Izzo S, Giorcelli J, Romeo E, Carnovale-scalzo C, Grillo LR, Facciolo F, Visca P, Papotti M, Righi L. Mesothelioma families without inheritance of a BAP1 predisposing mutation. Cancer Genetics 2016;209:381-7. [DOI: 10.1016/j.cancergen.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 87 |
Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res 2016;5:S160-5. [PMID: 29167760 DOI: 10.21037/tcr.2016.07.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 88 |
Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2017;3:421-427. [PMID: 28753773 DOI: 10.1016/j.euf.2016.06.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 89 |
Wang A, Papneja A, Hyrcza M, Al-Habeeb A, Ghazarian D. Gene of the month: BAP1. J Clin Pathol 2016;69:750-3. [PMID: 27235536 DOI: 10.1136/jclinpath-2016-203866] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 8.6] [Reference Citation Analysis]
|
